Evidence map›Paper›PMID 26295164›Full record

ArticlePloS one2015

Stereospecific Inhibitory Effects of CCG-1423 on the Cellular Events Mediated by Myocardin-Related Transcription Factor A.

Bunta Watanabe, Saki Minami, Hideaki Ishida, Ryuzo Yoshioka, Yoshiaki Nakagawa, Tsuyoshi Morita, Ken'ichiro Hayashi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Rho/SRF Inhibitor Modulates Mitochondrial Functions.International journal of molecular sciences · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Regulated methionine oxidation by monooxygenases.Free radical biology & medicine · 2017
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Bunta WatanabeInstitute for Chemical Research, Kyoto University, Uji, Kyoto, 611-0011, Japan.
Saki MinamiDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kyoto, 606-8502, Japan.
Hideaki IshidaToabo Corporation Co., Ltd., Crystal Tower 18F, 2-27, 1-Chome, Shiromi, Chuo-ku, Osaka, 540-6018, Japan.
Ryuzo YoshiokaNAHLS Co., Ltd., Room 2203, Kyodai Katsura Venture Plaza South Building, 1-39 Goryo-Ohara, Nishikyo-ku, Kyoto, 615-8245, Japan.
Yoshiaki NakagawaDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kyoto, 606-8502, Japan.
Tsuyoshi MoritaDepartment of RNA Biology and Neuroscience, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Ken'ichiro HayashiDepartment of RNA Biology and Neuroscience, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Kyoto University · JPOsaka University · JPKyoto Bunkyo University · JPToto (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CCG-1423 suppresses several pathological processes including cancer cell migration, tissue fibrosis, and the development of atherosclerotic lesions. These suppressions are caused by inhibition of myocardin-related transcription factor A (MRTF-A), which is a critical factor for epithelial-mesenchymal transition (EMT). CCG-1423 can therefore be a potent inhibitor for EMT. CCG-1423 and related compounds, CCG-100602 and CCG-203971 possess similar biological activities. Although these compounds are comprised of two stereoisomers, the differences in their biological activities remain to be assessed. To address this issue, we stereoselectively synthesized optically pure isomers of these compounds and validated their biological activities. The S-isomer of CCG-1423 rather than the R-isomer exhibited modestly but significantly higher inhibitory effects on the cellular events triggered by MRTF-A activation including serum response factor-mediated gene expression and cell migration of fibroblasts and B16F10 melanoma cells. Accordingly, the S-isomer of CCG-1423 more potently blocked the serum-induced nuclear import of MRTF-A than the R-isomer. No such difference was observed in cells treated with each of two stereoisomers of CCG-100602 or CCG-203971. We previously reported that the N-terminal basic domain (NB), which functions as a nuclear localization signal of MRTF-A, is a binding site for CCG-1423. Consistent with the biological activities of two stereoisomers of CCG-1423, docking simulation demonstrated that the S-isomer of CCG-1423 was more likely to bind to NB than the R-isomer. This is a first report demonstrating the stereospecific biological activities of CCG-1423.

Indexed as

AnilidesAnimalsBenzamidesBinding SitesCell DifferentiationCell LineCell MovementEpithelial-Mesenchymal TransitionFibroblastsGene ExpressionHumansMelanoma, ExperimentalMiceMolecular Docking SimulationMyoblastsNIH 3T3 CellsAnilidesBenzamidesCCG 1423MRTFA protein, humanTrans-Activators

Identifiers

PMID26295164
PMCPMC4546662
OpenAlexW2223084608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.